Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 60

1.

Brain copper storage after genetic long-term correction in a mouse model of Wilson disease.

Uerlings R, Moreno D, Murillo O, Gazquez C, Hernández-Alcoceba R, González-Aseguinolaza G, Weiskirchen R.

Neurol Genet. 2018 May 18;4(3):e243. doi: 10.1212/NXG.0000000000000243. eCollection 2018 Jun. No abstract available.

2.

Visualization of the therapeutic efficacy of a gene correction approach in Wilson's disease by laser-ablation inductively coupled mass spectrometry.

Moreno D, Murillo O, Gazquez C, Hernandez-Alcoceba R, Uerlings R, Gonzalez-Aseguinolaza G, Weiskirchen R.

J Hepatol. 2018 May;68(5):1088-1090. doi: 10.1016/j.jhep.2017.12.022. Epub 2018 Jan 6. No abstract available.

PMID:
29317295
3.

Adaptation of vectors and drug-inducible systems for controlled expression of transgenes in the tumor microenvironment.

Poutou J, Bunuales M, Gonzalez-Aparicio M, German B, Zugasti I, Hernandez-Alcoceba R.

J Control Release. 2017 Dec 28;268:247-258. doi: 10.1016/j.jconrel.2017.10.032. Epub 2017 Oct 24.

PMID:
29074407
4.

Improvement of Adeno-Associated Virus-Mediated Liver Transduction Efficacy by Regional Administration in Macaca fascicularis.

Zabaleta N, Salas D, Paramo M, Hommel M, Sier-Ferreira V, Hernandez-Alcoceba R, Prieto J, Bilbao JI, Gonzalez-Aseguinolaza G.

Hum Gene Ther Clin Dev. 2017 Jun;28(2):68-73. doi: 10.1089/humc.2016.183. Epub 2017 Mar 10.

PMID:
28285544
5.

Cancer stem cell-associated microRNAs: searching for markers and targets in hepatocellular carcinoma.

Hernandez-Alcoceba R, Fortes P.

Transl Gastroenterol Hepatol. 2016 Mar 16;1:16. doi: 10.21037/tgh.2016.03.11. eCollection 2016. No abstract available.

6.

X-box Binding Protein 1 Regulates Unfolded Protein, Acute-Phase, and DNA Damage Responses During Regeneration of Mouse Liver.

Argemí J, Kress TR, Chang HCY, Ferrero R, Bértolo C, Moreno H, González-Aparicio M, Uriarte I, Guembe L, Segura V, Hernández-Alcoceba R, Ávila MA, Amati B, Prieto J, Aragón T.

Gastroenterology. 2017 Apr;152(5):1203-1216.e15. doi: 10.1053/j.gastro.2016.12.040. Epub 2017 Jan 9.

PMID:
28082079
7.

Capsid-deficient alphaviruses generate propagative infectious microvesicles at the plasma membrane.

Ruiz-Guillen M, Gabev E, Quetglas JI, Casales E, Ballesteros-Briones MC, Poutou J, Aranda A, Martisova E, Bezunartea J, Ondiviela M, Prieto J, Hernandez-Alcoceba R, Abrescia NG, Smerdou C.

Cell Mol Life Sci. 2016 Oct;73(20):3897-916. doi: 10.1007/s00018-016-2230-1. Epub 2016 Apr 27.

PMID:
27117550
8.

A Versatile Vector for In Vivo Monitoring of Type I Interferon Induction and Signaling.

Nistal-Villan E, Poutou J, Rodríguez-Garcia E, Buñuales M, Carte-Abad B, Prieto J, Gonzalez-Aseguinolaza G, Hernandez-Alcoceba R, Larrea E.

PLoS One. 2016 Mar 23;11(3):e0152031. doi: 10.1371/journal.pone.0152031. eCollection 2016.

9.

Gene therapy approaches against cancer using in vivo and ex vivo gene transfer of interleukin-12.

Hernandez-Alcoceba R, Poutou J, Ballesteros-Briones MC, Smerdou C.

Immunotherapy. 2016 Feb;8(2):179-98. doi: 10.2217/imt.15.109. Epub 2016 Jan 20. Review.

PMID:
26786809
10.

Enhanced therapeutic effect using sequential administration of antigenically distinct oncolytic viruses expressing oncostatin M in a Syrian hamster orthotopic pancreatic cancer model.

Nistal-Villan E, Bunuales M, Poutou J, Gonzalez-Aparicio M, Bravo-Perez C, Quetglas JI, Carte B, Gonzalez-Aseguinolaza G, Prieto J, Larrea E, Hernandez-Alcoceba R.

Mol Cancer. 2015 Dec 16;14:210. doi: 10.1186/s12943-015-0479-x.

11.

Long-term metabolic correction of Wilson's disease in a murine model by gene therapy.

Murillo O, Luqui DM, Gazquez C, Martinez-Espartosa D, Navarro-Blasco I, Monreal JI, Guembe L, Moreno-Cermeño A, Corrales FJ, Prieto J, Hernandez-Alcoceba R, Gonzalez-Aseguinolaza G.

J Hepatol. 2016 Feb;64(2):419-426. doi: 10.1016/j.jhep.2015.09.014. Epub 2015 Sep 25.

PMID:
26409215
12.

Safety and antitumor effect of oncolytic and helper-dependent adenoviruses expressing interleukin-12 variants in a hamster pancreatic cancer model.

Poutou J, Bunuales M, Gonzalez-Aparicio M, Garcia-Aragoncillo E, Quetglas JI, Casado R, Bravo-Perez C, Alzuguren P, Hernandez-Alcoceba R.

Gene Ther. 2015 Sep;22(9):696-706. doi: 10.1038/gt.2015.45. Epub 2015 May 4.

PMID:
25938192
13.

Transient depletion of specific immune cell populations to improve adenovirus-mediated transgene expression in the liver.

Alzuguren P, Hervas-Stubbs S, Gonzalez-Aseguinolaza G, Poutou J, Fortes P, Mancheno U, Bunuales M, Olagüe C, Razquin N, Van Rooijen N, Enguita M, Hernandez-Alcoceba R.

Liver Int. 2015 Apr;35(4):1274-89. doi: 10.1111/liv.12571. Epub 2014 May 10.

PMID:
24754307
14.

Combining virotherapy and angiotherapy for the treatment of breast cancer.

Bazan-Peregrino M, Sainson RC, Carlisle RC, Thoma C, Waters RA, Arvanitis C, Harris AL, Hernandez-Alcoceba R, Seymour LW.

Cancer Gene Ther. 2013 Aug;20(8):461-8. doi: 10.1038/cgt.2013.41. Epub 2013 Jul 12.

PMID:
23846253
15.

Cytokines for the treatment of gastrointestinal cancers: clinical experience and new perspectives.

Hernandez-Alcoceba R, Sangro B, Berraondo P, Gonzalez-Aseguinolaza G, Prieto J.

Expert Opin Investig Drugs. 2013 Jul;22(7):827-41. doi: 10.1517/13543784.2013.793307. Epub 2013 Apr 18. Review.

PMID:
23594171
16.

Target-mediated disposition model describing the dynamics of IL12 and IFNγ after administration of a mifepristone-inducible adenoviral vector for IL-12 expression in mice.

Parra-Guillen ZP, Janda A, Alzuguren P, Berraondo P, Hernandez-Alcoceba R, Troconiz IF.

AAPS J. 2013 Jan;15(1):183-94. doi: 10.1208/s12248-012-9423-9. Epub 2012 Nov 8.

17.

Evaluation of monocytes as carriers for armed oncolytic adenoviruses in murine and Syrian hamster models of cancer.

Bunuales M, Garcia-Aragoncillo E, Casado R, Quetglas JI, Hervas-Stubbs S, Bortolanza S, Benavides-Vallve C, Ortiz-de-Solorzano C, Prieto J, Hernandez-Alcoceba R.

Hum Gene Ther. 2012 Dec;23(12):1258-68. doi: 10.1089/hum.2012.043. Epub 2012 Oct 26.

18.
19.

Modulation of regulatory T-cell activity in combination with interleukin-12 increases hepatic tolerogenicity in woodchucks with chronic hepatitis B.

Otano I, Suarez L, Dotor J, Gonzalez-Aparicio M, Crettaz J, Olagüe C, Vales A, Riezu JI, Larrea E, Borras F, Benito A, Hernandez-Alcoceba R, Menne S, Prieto J, González-Aseguinolaza G.

Hepatology. 2012 Aug;56(2):474-83. doi: 10.1002/hep.25667. Epub 2012 Jul 2.

PMID:
22334260
20.

Characterization of herpes simplex virus 1 strains as platforms for the development of oncolytic viruses against liver cancer.

Argnani R, Marconi P, Volpi I, Bolanos E, Carro E, Ried C, Santamaria E, Pourchet A, Epstein AL, Brocker T, Corrales FJ, Manservigi R, Goicoechea I, Foschini M, Hernandez-Alcoceba R.

Liver Int. 2011 Nov;31(10):1542-53. doi: 10.1111/j.1478-3231.2011.02628.x. Epub 2011 Aug 25.

PMID:
22093330
21.

Self-inactivating helper virus for the production of high-capacity adenoviral vectors.

Gonzalez-Aparicio M, Mauleon I, Alzuguren P, Bunuales M, Gonzalez-Aseguinolaza G, San Martín C, Prieto J, Hernandez-Alcoceba R.

Gene Ther. 2011 Nov;18(11):1025-33. doi: 10.1038/gt.2011.58. Epub 2011 Apr 28.

PMID:
21525953
22.

Recent advances in oncolytic virus design.

Hernández-Alcoceba R.

Clin Transl Oncol. 2011 Apr;13(4):229-39. doi: 10.1007/s12094-011-0647-4. Review.

PMID:
21493183
23.

Gene therapy for HCV/HBV-induced hepatocellular carcinoma.

Smerdou C, Menne S, Hernandez-Alcoceba R, Gonzalez-Aseguinolaza G.

Curr Opin Investig Drugs. 2010 Dec;11(12):1368-77. Review.

PMID:
21154119
24.

Novel tumour-specific promoters for transcriptional targeting of hepatocellular carcinoma by herpes simplex virus vectors.

Foka P, Pourchet A, Hernandez-Alcoceba R, Doumba PP, Pissas G, Kouvatsis V, Dalagiorgou G, Kazazi D, Marconi P, Foschini M, Manservigi R, Konstadoulakis MM, Koskinas J, Epstein AL, Mavromara P.

J Gene Med. 2010 Dec;12(12):956-67. doi: 10.1002/jgm.1519.

PMID:
21104973
25.

Oxaliplatin in combination with liver-specific expression of interleukin 12 reduces the immunosuppressive microenvironment of tumours and eradicates metastatic colorectal cancer in mice.

Gonzalez-Aparicio M, Alzuguren P, Mauleon I, Medina-Echeverz J, Hervas-Stubbs S, Mancheno U, Berraondo P, Crettaz J, Gonzalez-Aseguinolaza G, Prieto J, Hernandez-Alcoceba R.

Gut. 2011 Mar;60(3):341-9. doi: 10.1136/gut.2010.211722. Epub 2010 Sep 20.

PMID:
20855451
26.

Design of virotherapy for effective tumor treatment.

Garcia-Aragoncillo E, Hernandez-Alcoceba R.

Curr Opin Mol Ther. 2010 Aug;12(4):403-11. Review.

PMID:
20677091
27.

Human adenovirus replication in immunocompetent Syrian hamsters can be attenuated with chlorpromazine or cidofovir.

Diaconu I, Cerullo V, Escutenaire S, Kanerva A, Bauerschmitz GJ, Hernandez-Alcoceba R, Pesonen S, Hemminki A.

J Gene Med. 2010 May;12(5):435-45. doi: 10.1002/jgm.1453.

PMID:
20440754
28.

Growth inhibition of human multiple myeloma cells by an oncolytic adenovirus carrying the CD40 ligand transgene.

Fernandes MS, Gomes EM, Butcher LD, Hernandez-Alcoceba R, Chang D, Kansopon J, Newman J, Stone MJ, Tong AW.

Clin Cancer Res. 2009 Aug 1;15(15):4847-56. doi: 10.1158/1078-0432.CCR-09-0451. Epub 2009 Jul 21.

29.

Identification of replication-competent HSV-1 Cgal+ strain targets in a mouse model of human hepatocarcinoma xenograft.

Santamaría E, Mora MI, Carro-Roldán E, Molina M, Fernández-Irigoyen J, Marconi P, Manservigi R, Greco A, Epstein AL, Prieto J, Hernández-Alcoceba R, Corrales FJ.

J Proteomics. 2009 Nov 2;73(1):153-60. doi: 10.1016/j.jprot.2009.06.008. Epub 2009 Jun 21.

PMID:
19540947
30.

Deletion of the E3-6.7K/gp19K region reduces the persistence of wild-type adenovirus in a permissive tumor model in Syrian hamsters.

Bortolanza S, Bunuales M, Alzuguren P, Lamas O, Aldabe R, Prieto J, Hernandez-Alcoceba R.

Cancer Gene Ther. 2009 Sep;16(9):703-12. doi: 10.1038/cgt.2009.12. Epub 2009 Feb 20.

PMID:
19229289
31.

Antitumor activity of an oncolytic adenoviral-CD40 ligand (CD154) transgene construct in human breast cancer cells.

Gomes EM, Rodrigues MS, Phadke AP, Butcher LD, Starling C, Chen S, Chang D, Hernandez-Alcoceba R, Newman JT, Stone MJ, Tong AW.

Clin Cancer Res. 2009 Feb 15;15(4):1317-25. doi: 10.1158/1078-0432.CCR-08-1360.

32.

Treatment of pancreatic cancer with an oncolytic adenovirus expressing interleukin-12 in Syrian hamsters.

Bortolanza S, Bunuales M, Otano I, Gonzalez-Aseguinolaza G, Ortiz-de-Solorzano C, Perez D, Prieto J, Hernandez-Alcoceba R.

Mol Ther. 2009 Apr;17(4):614-22. doi: 10.1038/mt.2009.9. Epub 2009 Feb 17.

33.

Evaluation of bioluminescent imaging for noninvasive monitoring of colorectal cancer progression in the liver and its response to immunogene therapy.

Zabala M, Alzuguren P, Benavides C, Crettaz J, Gonzalez-Aseguinolaza G, Ortiz de Solorzano C, Gonzalez-Aparicio M, Kramer MG, Prieto J, Hernandez-Alcoceba R.

Mol Cancer. 2009 Jan 7;8:2. doi: 10.1186/1476-4598-8-2.

34.

Identification of replication-competent HSV-1 Cgal+ strain signaling targets in human hepatoma cells by functional organelle proteomics.

Santamaría E, Mora MI, Potel C, Fernández-Irigoyen J, Carro-Roldán E, Hernández-Alcoceba R, Prieto J, Epstein AL, Corrales FJ.

Mol Cell Proteomics. 2009 Apr;8(4):805-15. doi: 10.1074/mcp.M800202-MCP200. Epub 2008 Dec 19.

35.

Lethality in an anti-angiogenic tumor gene therapy model upon constitutive but not inducible expression of the soluble vascular endothelial growth factor receptor 1.

Sivanandam VG, Stephen SL, Hernandez-Alcoceba R, Alzuguren P, Zabala M, van Rooijen N, Qian C, Berger I, Gross ML, Prieto J, Kochanek S.

J Gene Med. 2008 Oct;10(10):1083-91. doi: 10.1002/jgm.1244.

PMID:
18720430
36.

Comparison of molecular strategies for breast cancer virotherapy using oncolytic adenovirus.

Bazan-Peregrino M, Carlisle RC, Hernandez-Alcoceba R, Iggo R, Homicsko K, Fisher KD, Halldén G, Mautner V, Shen Y, Seymour LW.

Hum Gene Ther. 2008 Sep;19(9):873-86. doi: 10.1089/hum.2008.047.

PMID:
18710328
37.

Interleukin-12 inhibits liver-specific drug-inducible systems in vivo.

Reboredo M, Zabala M, Mauleon I, De Las Rivas J, Kreppel F, Kochanek S, Prieto J, Hernandez-Alcoceba R, Kramer MG.

Gene Ther. 2008 Feb;15(4):277-88. Epub 2007 Nov 22.

PMID:
18033307
38.

Human adenovirus replicates in immunocompetent models of pancreatic cancer in Syrian hamsters.

Bortolanza S, Alzuguren P, Buñuales M, Qian C, Prieto J, Hernandez-Alcoceba R.

Hum Gene Ther. 2007 Aug;18(8):681-90.

PMID:
17658991
39.

Gene therapy of liver cancer.

Hernández-Alcoceba R, Sangro B, Prieto J.

Ann Hepatol. 2007 Jan-Mar;6(1):5-14. Review.

PMID:
17297424
40.

Gene therapy of liver cancer.

Hernandez-Alcoceba R, Sangro B, Prieto J.

World J Gastroenterol. 2006 Oct 14;12(38):6085-97. Review.

41.

Intrahepatic injection of adenovirus reduces inflammation and increases gene transfer and therapeutic effect in mice.

Crettaz J, Berraondo P, Mauleón I, Ochoa-Callejero L, Shankar V, Barajas M, van Rooijen N, Kochanek S, Qian C, Prieto J, Hernández-Alcoceba R, González-Aseguinolaza G.

Hepatology. 2006 Sep;44(3):623-32. Erratum in: Hepatology. 2011 Dec;54(6):2280. Ochoa, Laura [corrected to Ochoa-Callejero, L].

PMID:
16941711
42.

Recombinant adenoviral vectors turn on the type I interferon system without inhibition of transgene expression and viral replication.

Huarte E, Larrea E, Hernández-Alcoceba R, Alfaro C, Murillo O, Arina A, Tirapu I, Azpilicueta A, Hervás-Stubbs S, Bortolanza S, Pérez-Gracia JL, Civeira MP, Prieto J, Riezu-Boj JI, Melero I.

Mol Ther. 2006 Jul;14(1):129-38. Epub 2006 Apr 19.

43.

Antisense oligonucleotides and the rational design of new antitumor drugs.

Prieto J, Hernández-Alcoceba R.

Rev Esp Enferm Dig. 2005 Jul;97(7):467-71. English, Spanish. No abstract available.

44.

An oncolytic adenovirus controlled by a modified telomerase promoter is attenuated in telomerase-negative cells, but shows reduced activity in cancer cells.

Bortolanza S, Qian C, Kramer MG, Gomar C, Prieto J, Farinati F, Hernandez-Alcoceba R.

J Mol Med (Berl). 2005 Sep;83(9):736-47. Epub 2005 Jun 23.

PMID:
15976917
45.

In utero gene therapy: current challenges and perspectives.

Waddington SN, Kramer MG, Hernandez-Alcoceba R, Buckley SM, Themis M, Coutelle C, Prieto J.

Mol Ther. 2005 May;11(5):661-76. Review.

46.

Gene therapy of liver diseases.

Prieto J, Qian C, Hernandez-Alcoceba R, Gonzalez-Aseguinolaza G, Mazzolini G, Sangro B, Kramer MG.

Expert Opin Biol Ther. 2004 Jul;4(7):1073-91. Review.

PMID:
15268675
47.

Optimization of the Tet-on system to regulate interleukin 12 expression in the liver for the treatment of hepatic tumors.

Zabala M, Wang L, Hernandez-Alcoceba R, Hillen W, Qian C, Prieto J, Kramer MG.

Cancer Res. 2004 Apr 15;64(8):2799-804.

48.

Prolonged and inducible transgene expression in the liver using gutless adenovirus: a potential therapy for liver cancer.

Wang L, Hernández-Alcoceba R, Shankar V, Zabala M, Kochanek S, Sangro B, Kramer MG, Prieto J, Qian C.

Gastroenterology. 2004 Jan;126(1):278-89.

PMID:
14699506
49.

Specific oncolytic effect of a new hypoxia-inducible factor-dependent replicative adenovirus on von Hippel-Lindau-defective renal cell carcinomas.

Cuevas Y, Hernández-Alcoceba R, Aragones J, Naranjo-Suárez S, Castellanos MC, Esteban MA, Martín-Puig S, Landazuri MO, del Peso L.

Cancer Res. 2003 Oct 15;63(20):6877-84.

50.

QSAR-derived choline kinase inhibitors: how rational can antiproliferative drug design be?

Campos J, Núñez MC, Conejo-García A, Sánchez-Martín RM, Hernández-Alcoceba R, Rodríguez-González A, Lacal JC, Gallo MA, Espinosa A.

Curr Med Chem. 2003 Jul;10(13):1095-112. Review.

PMID:
12678804

Supplemental Content

Loading ...
Support Center